WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2010065400) CANCER BIOMARKER AND METHODS OF USING THEREOF
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

What is claimed is:

1. A method of identifying a cancer stem cell in a biological sample comprising assaying for the levels of Octl in the biological sample, wherein an increase in the amount of Octl in the biological sample as compared to a control is an indication of the presence of cancer stem cells in the biological sample.

2. The method of claim 1, wherein Octl levels are detected by immunohistochemistry.

3. The method of claim 1, wherein the biological sample is from a subject diagnosed with cancer.

4. The method of claim 2, wherein the biological sample comprises a tumor biopsy.

5. The method of claim 2, wherein the cancer comprises an adenocarcinoma.

6. The method of claim 5, wherein the adenocarcinoma comprises a colon adenocarcinoma, a breast carcinoma, or a lung carcinoma.

7. A method of treating cancer stem cells in a subject, comprising administering to the subject an inhibitor of Octl activity.

8. The method of claim 7, wherein the subject has been diagnosed as having cancer stem cells.

9. The method of claim 8, wherein the subject has been diagnosed as having cancer cells expressing high levels of Octl as compared to a control.

10. The method of claim 7, wherein the subject has undergone or been prescribed irradiation, chemotherapy, or a combination thereof.

11. A method of identifying an agent for use in treating a cancer stem cell comprising contacting a sample comprising Octl with a candidate agent and assaying for Octl activity in the sample, wherein a decrease in Octl activity in the sample is an indication that the candidate agent is an effective agent for use in treating cancer stem cells.

12. The method of claim 11, wherein the method comprises assaying for the ability of Octl to bind target DNA in the presence of the candidate agent, wherein a decrease in Octl binding to the target DNA is an indication that the candidate agent is an effective agent for use in treating cancer stem cells.

13. The method of claim 12, wherein the target DNA is the Octl-binding site in the immediate promoter region of the Aldhlal promoter.